China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financi...(n) which was within our targeted r...),Health

Date:9/1/2009

n) which was within our targeted range of RMB410.0 million to RMB420.0 million. -- Diluted loss from continuing operations per ADS* was RMB0.08 (US$0.01). -- Non-GAAP diluted earnings from continuing operations per ADS*, as defined below, were RMB15.97 (US$2.34) which exceeded the high end of our targeted range of RMB15.13. -- Annual cash dividend of US$0.55 per ADS* for FY2008 was declared which increased by 10.0% as compared to annual cash dividend of US$0.5 per ADS last year. * One American Depositary Share ("ADS") = 10 ordinary shares See "Non-GAAP Measure Disclosures" below, where the impact of certain items on reported results is discussed.

"In FY2008, we achieved significant operational milestones," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We continue to believe that China IVD market is significantly under-developed and under-penetrated. We are confident in our positioning as an advanced in-vitro diagnostic company in China to capture the enormous growth potentials in this business segment over the next 10 years. We also maintain our steady dividend policy to reward our shareholders despite challenging circumstances."

4Q FY2008 Unaudited Financial Results

The Company reported revenues from continuing operations of RMB248.6 million (US$36.4 million) for 4Q FY2008, representing a 37.3% increase from the corresponding period of FY2007.

The Company's revenues from continuing operations are currently generated from two product lines, ECLIA diagnostic systems and FISH diagnostic systems.

ECLIA system sales for 4Q FY2008 were RMB139.0 million (US$20.3 million), representing a 23.9% increase from the corresponding period of FY2007. The year-over-year growth in the ECLIA system sales was primarily due to the increasing utilization of the Company's ECLIA an
'/>"/>

SOURCE China Medical Technologies, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI